{"id":295566,"date":"2023-06-15T00:00:00","date_gmt":"2023-06-15T00:00:00","guid":{"rendered":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0005-2023-biopharma-human-immunodeficiency-virus-current-treatment-current-treatment-physician\/"},"modified":"2026-03-31T10:32:49","modified_gmt":"2026-03-31T10:32:49","slug":"cutrid0005-2023-biopharma-human-immunodeficiency-virus-current-treatment-current-treatment-physician-insights-human","status":"publish","type":"report","link":"https:\/\/clarivate.com\/life-sciences-healthcare\/report\/cutrid0005-2023-biopharma-human-immunodeficiency-virus-current-treatment-current-treatment-physician-insights-human\/","title":{"rendered":"Human Immunodeficiency Virus &#8211; Current treatment &#8211; Current Treatment: Physician Insights &#8211; Human Immunodeficiency Virus (US)"},"content":{"rendered":"<p>The human immunodeficiency virus (<abbr title=\"human immunodeficiency virus\">HIV<\/abbr>) therapy market is dynamic and growing. With the launches of many effective antiretroviral therapies (<abbr title=\"antiretroviral therapy\">ART<\/abbr>s), such as Gilead\u2019s Biktarvy and ViiV\u2019s Dovato, Juluca, and Cabenuva (long-acting once-monthly injection), safety and tolerability have become the key differentiating attributes among <abbr title=\"antiretroviral therapy\">ART<\/abbr> regimens. For most patients, current <abbr title=\"antiretroviral therapy\">ART<\/abbr>s such as single-tablet regimens (<abbr title=\"single-tablet regimen\">STR<\/abbr>s) have achieved maximal antiretroviral efficacy and tolerability, changing <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> infection from a fatal disease to a tolerable chronic condition. Despite this achievement, adherence to regular oral medicine consumption remains a problem; however, the recent label expansion of Cabenuva, a novel medication delivery strategy, is poised to transform the treatment landscape, reducing the once-daily pill burden to only six intramuscular injections each year. Other recently approved long-acting options that address the adherence burden, such as Gilead\u2019s Sunlenca for heavily treatment-experienced patients with multidrug-resistant <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>-1 infection, also aim to transform the treatment landscape. This report focuses on current treatment and the anticipated use of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> treatment regimens by capturing patient market share data, current prescribing trends, and anticipated changes in prescribing and treatment behavior. The key prescribing drivers and barriers, and salesforce performance for key brands, will be evaluated. This content will quantitatively explore the current treatment of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> as marketed <abbr title=\"antiretroviral therapy\">ART<\/abbr>s and novel agents advance in the pipeline.<\/p>\n<p><strong>Questions answered<\/strong><\/p>\n<ul class=\"round-bullets\">\n<li>Which comorbidities are most common among surveyed physicians\u2019 patient populations?<\/li>\n<li>How do physicians approach the management of newly diagnosed <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> patients and those switching treatment?<\/li>\n<li>Which patients receive which <abbr title=\"antiretroviral therapy\">ART<\/abbr> based on their CD4 count level?<\/li>\n<li>Which patients are being prescribed <abbr title=\"single-tablet regimen\">STR<\/abbr>s (e.g., Gilead\u2019s Biktarvy, Genvoya, and Odefsey; ViiV&#8217;s Juluca and Dovato) and in which line(s) of therapy? What factors drive the movement of <abbr title=\"human immunodeficiency virus\">HIV<\/abbr> patients through lines of therapy?<\/li>\n<li>Which <abbr title=\"antiretroviral therapy\">ART<\/abbr>s are the patient-share leaders in <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>? How are key <abbr title=\"single-tablet regimen\">STR<\/abbr>s positioned in surveyed physicians\u2019 treatment algorithms?<\/li>\n<li>What is the sequencing of treatment for <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>?<\/li>\n<li>What are the most influential drivers of treatment selection for <abbr title=\"human immunodeficiency virus\">HIV<\/abbr>?<\/li>\n<li>What are the infectious disease physician-reported factors determining current prescribing patterns and recent \/ anticipated changes?<\/li>\n<\/ul>\n<p><strong>Content highlights<\/strong><\/p>\n<p>Geography: United States<\/p>\n<p>Key drugs covered: Biktarvy, Dovato, Juluca, Cabenuva<\/p>\n<p><strong>Product description<\/strong><\/p>\n<p>Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behaviour, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n","protected":false},"template":"","class_list":["post-295566","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-human-immunodeficiency-virus","biopharma-product-current-treatment","biopharma-geography-us","biopharma-date-975"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295566","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295566\/revisions"}],"predecessor-version":[{"id":295796,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/295566\/revisions\/295796"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=295566"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}